Press Release
Akebia Prevails in Additional European Patent Dispute
"While we believe that this patent would not have impacted our ability
to commercialize in
In
In other news today, Akebia provided details related to its
About Akebia Therapeutics
Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements include those about Akebia's strategy, future
plans and prospects, including statements regarding the potential
indications and benefits of vadadustat, development plans for
vadadustat, the progress toward securing a geographic collaboration and
the timing of the Opposition Division's written decision. The words
"anticipate," "appear," "believe," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement, including the risk that existing preclinical
and clinical data may not be predictive of the results of ongoing or
later clinical trials; the ability of Akebia to successfully complete
the clinical development of vadadustat; the funding required to develop
Akebia's product candidates and operate the company, and the actual
expenses associated therewith; the cost of the Phase 3 studies of
vadadustat and the availability of financing to cover such costs; the
timing and content of decisions made by the FDA and other regulatory
authorities; the rate of enrollment in clinical studies of vadadustat;
the actual time it takes to prepare for and initiate clinical studies;
Akebia's ability to negotiate commercially reasonable terms with a
geographic collaboration partner; the success of competitors in
developing product candidates for diseases for which Akebia is currently
developing its product candidates; the actual time it takes for the
Opposition Division to issue its written decision; and Akebia's ability
to obtain, maintain and enforce patent and other intellectual property
protection for vadadustat. Other risks and uncertainties include those
identified under the heading "Risk Factors" in Akebia's Quarterly Report
on Form 10-Q for the quarter ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20161212005339/en/
Akebia:
AJ Gosselin, +1 617-844-6130
Manager, Corporate
Communications
agosselin@akebia.com
Source:
News Provided by Acquire Media
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax